Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01961713 · ClinicalTrials.gov registry record

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

A clinical trial of Prostate Cancer, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT01961713: Recruiting study of Prostate Cancer, sponsored by Massachusetts General Hospital.

NCT01961713 is a study of Prostate Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 200 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01961713, a study of Prostate Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small number of cells into the bloodstream every day. These are called circulating tumor cells (CTCs). Some early studies indicate the amount and type of CTCs in the blood can help determine the status of the tumor itself and the way it is responding to treatment. In this study, the investigators will compare the number of CTCs in the blood at different time frames before and after surgery to remove the prostate.

Primary Outcome

To evaluate the relationship between pre-operative CTC quantity and pathologic stage in men with early stage prostate cancer undergoing prostatectomy. Processing of the pathology specimen will require up to 2 weeks after surgery.

Conditions Studied

Study Locations (1)

Massachusetts

  • Massachsuetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2010-04
Est. Completion 2025-12
Massachusetts General Hospital

2,032 total trials

What NCT01961713 shows while recruiting

NCT01961713 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT01961713 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01961713 about?

NCT01961713 is a clinical study titled "Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy". This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small number of cells into the bloodstream every day. These are called circulating tumor cells (CTCs). Some ...

What is the current status of trial NCT01961713?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2010-04. Estimated completion is 2025-12.

What conditions does trial NCT01961713 study?

This clinical trial studies the following conditions: Prostate Cancer.

Who is sponsoring clinical trial NCT01961713?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01961713 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01961713's enrollment target sits among peer trials

200 221st of 735 higher than 504 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01961713, the US trial registry maintained by the National Library of Medicine. NCT01961713 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.